Monoclonal antibodies block transmission of genetically diverse Plasmodium falciparum strains to mosquitoes
暂无分享,去创建一个
M. Huynen | T. Bousema | G. van Gemert | M. M. Jore | R. Sauerwein | R. Dabiré | I. Morlais | S. Nsango | T. Churcher | M. G. van de Vegte-Bolmer | L. Meerstein-Kessel | E. Locke | J. D. Challenger | N. Teyssier | E. Duarte | D. Da | Elias M Duarte | R. D. de Jong | M. van de Vegte-Bolmer | Lisette Meerstein-Kessel | Noam B Teyssier
[1] William L. Hamilton,et al. An open dataset of Plasmodium falciparum genome variation in 7,000 worldwide samples. , 2021, Wellcome open research.
[2] T. Bousema,et al. A portfolio of geographically distinct laboratory-adapted Plasmodium falciparum clones with consistent infection rates in Anopheles mosquitoes , 2021, Malaria journal.
[3] N. Tolia,et al. A human monoclonal antibody blocks malaria transmission and defines a highly conserved neutralizing epitope on gametes , 2021, Nature Communications.
[4] P. Scaria,et al. Pfs230 yields higher malaria transmission–blocking vaccine activity than Pfs25 in humans but not mice , 2021, The Journal of clinical investigation.
[5] D. Carter,et al. Reassessing therapeutic antibodies for neglected and tropical diseases , 2020, PLoS neglected tropical diseases.
[6] T. Bousema,et al. Immunity against sexual stage Plasmodium falciparum and Plasmodium vivax parasites , 2019, Immunological reviews.
[7] W. Schief,et al. Potent antibody lineage against malaria transmission elicited by human vaccination with Pfs25 , 2019, Nature Communications.
[8] G. van Gemert,et al. Pfs230 and Pfs48/45 Fusion Proteins Elicit Strong Transmission-Blocking Antibody Responses Against Plasmodium falciparum , 2019, Front. Immunol..
[9] Simon C. Potter,et al. The EMBL-EBI search and sequence analysis tools APIs in 2019 , 2019, Nucleic Acids Res..
[10] C. King,et al. Expression and purification optimization of an N-terminal Pfs230 transmission-blocking vaccine candidate , 2019, Protein expression and purification.
[11] T. Bousema,et al. Two-Faced Immunity? The Evidence for Antibody Enhancement of Malaria Transmission. , 2019, Trends in parasitology.
[12] T. Bousema,et al. Plasmodium falciparum Gametocyte Enrichment in Peripheral Blood Samples by Magnetic Fractionation: Gametocyte Yields and Possibilities to Reuse Columns , 2019, The American journal of tropical medicine and hygiene.
[13] A. Semesi,et al. Structural delineation of potent transmission-blocking epitope I on malaria antigen Pfs48/45 , 2018, Nature Communications.
[14] C. Ockenhouse,et al. Safety and immunogenicity of a plant-produced Pfs25 virus-like particle as a transmission blocking vaccine against malaria: A Phase 1 dose-escalation study in healthy adults , 2018, Vaccine.
[15] Erin E Gabriel,et al. Safety and immunogenicity of Pfs25H-EPA/Alhydrogel, a transmission-blocking vaccine against Plasmodium falciparum: a randomised, double-blind, comparator-controlled, dose-escalation study in healthy Malian adults. , 2018, The Lancet. Infectious diseases.
[16] D. Wirth,et al. Transmission of molecularly undetectable circulating parasite clones leads to high infection complexity in mosquitoes post feeding☆ , 2018, International journal for parasitology.
[17] Alex B. Miller,et al. Author Correction: A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite , 2018, Nature Medicine.
[18] V. A. Stewart,et al. A deep sequencing approach to estimate Plasmodium falciparum complexity of infection (COI) and explore apical membrane antigen 1 diversity , 2017, Malaria Journal.
[19] J. Bailey,et al. SeekDeep: single-base resolution de novo clustering for amplicon deep sequencing , 2017, Nucleic acids research.
[20] B. F. Hall,et al. malERA: An updated research agenda for malaria elimination and eradication , 2017, PLoS medicine.
[21] M. Mathieu,et al. IgG Fc engineering to modulate antibody effector functions , 2017, Protein & Cell.
[22] M. Huynen,et al. Modest heterologous protection after Plasmodium falciparum sporozoite immunization: a double-blind randomized controlled clinical trial , 2017, BMC Medicine.
[23] T. Lefèvre,et al. Evaluation of two lead malaria transmission blocking vaccine candidate antibodies in natural parasite-vector combinations , 2017, Scientific Reports.
[24] P. V. van Genderen,et al. Infectivity of Plasmodium falciparum sporozoites determines emerging parasitemia in infected volunteers , 2017, Science Translational Medicine.
[25] M. Fay,et al. Safety and Immunogenicity of Pfs25-EPA/Alhydrogel®, a Transmission Blocking Vaccine against Plasmodium falciparum: An Open Label Study in Malaria Naïve Adults , 2016, PloS one.
[26] X. Ambroggio,et al. Structural and Immunological Characterization of Recombinant 6-Cysteine Domains of the Plasmodium falciparum Sexual Stage Protein Pfs230* , 2016, The Journal of Biological Chemistry.
[27] Dennis R Burton,et al. Broadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design. , 2016, Annual review of immunology.
[28] T. Bousema,et al. Transmission blocking malaria vaccines: Assays and candidates in clinical development. , 2015, Vaccine.
[29] A. Nicosia,et al. Comparative Assessment of Transmission-Blocking Vaccine Candidates against Plasmodium falciparum , 2015, Scientific Reports.
[30] T. Bousema,et al. The relevance and applicability of oocyst prevalence as a read-out for mosquito feeding assays , 2013, Scientific Reports.
[31] X. Su,et al. Anti-Pfs25 Human Plasma Reduces Transmission of Plasmodium falciparum Isolates That Have Diverse Genetic Backgrounds , 2013, Infection and Immunity.
[32] M. Fay,et al. Qualification of Standard Membrane-Feeding Assay with Plasmodium falciparum Malaria and Potential Improvements for Future Assays , 2013, PloS one.
[33] S. Hoffman,et al. NF135.C10: A New Plasmodium falciparum Clone for Controlled Human Malaria Infections , 2012, The Journal of infectious diseases.
[34] R. Sinden,et al. Measuring the blockade of malaria transmission--an analysis of the Standard Membrane Feeding Assay. , 2012, International journal for parasitology.
[35] T. Tsuboi,et al. A Plant-Produced Pfs230 Vaccine Candidate Blocks Transmission of Plasmodium falciparum , 2011, Clinical and Vaccine Immunology.
[36] O. Doumbo,et al. Blood stage vaccines for Plasmodium falciparum , 2010, Human vaccines.
[37] Eileen Kraemer,et al. PlasmoDB: a functional genomic database for malaria parasites , 2008, Nucleic Acids Res..
[38] M. Fay,et al. Phase 1 Trial of Malaria Transmission Blocking Vaccine Candidates Pfs25 and Pvs25 Formulated with Montanide ISA 51 , 2008, PloS one.
[39] Didier Fontenille,et al. Population genetic structure of Plasmodium falciparum in the two main African vectors, Anopheles gambiae and Anopheles funestus , 2007, Proceedings of the National Academy of Sciences.
[40] Siarhei Maslau,et al. Structural models for the protein family characterized by gamete surface protein Pfs230 of Plasmodium falciparum. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[41] Leszek Rychlewski,et al. FFAS03: a server for profile–profile sequence alignments , 2005, Nucleic Acids Res..
[42] G. Crooks,et al. WebLogo: a sequence logo generator. , 2004, Genome research.
[43] D. Conway,et al. Extreme geographical fixation of variation in the Plasmodium falciparum gamete surface protein gene Pfs48/45 compared with microsatellite loci. , 2001, Molecular and biochemical parasitology.
[44] J. Meuwissen,et al. Plasmodium falciparum: a comparison of the activity of Pfs230-specific antibodies in an assay of transmission-blocking immunity and specific competition ELISAs. , 1995, Experimental parasitology.
[45] R. Sauerwein,et al. Transmission blockade of Plasmodium falciparum malaria by anti-Pfs230-specific antibodies is isotype dependent , 1995, Infection and immunity.
[46] J. Meis,et al. A scanning electron microscopic study of the sporogonic development of Plasmodium falciparum in Anopheles stephensi. , 1992, Acta tropica.
[47] R. Carter,et al. Genetic hybrids of Plasmodium falciparum identified by amplification of genomic DNA from single oocysts. , 1991, Molecular and biochemical parasitology.
[48] P. Barr,et al. Recombinant Pfs25 protein of Plasmodium falciparum elicits malaria transmission-blocking immunity in experimental animals , 1991, The Journal of experimental medicine.
[49] J. Meuwissen,et al. Infectivity of cultured Plasmodium falciparum gametocytes to mosquitoes , 1989, Parasitology.
[50] M. Smits,et al. Sequential expression of antigens on sexual stages of Plasmodium falciparum accessible to transmission-blocking antibodies in the mosquito , 1985, The Journal of experimental medicine.
[51] R. Carter,et al. Target antigens in malaria transmission blocking immunity. , 1984, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.
[52] T. Burkot,et al. Target antigens of transmission-blocking immunity on gametes of plasmodium falciparum , 1983, The Journal of experimental medicine.
[53] R. Sinden. The cell biology of sexual development in Plasmodium , 1983, Parasitology.
[54] R. Sauerwein,et al. Plasmodium falciparum: production and characterization of rat monoclonal antibodies specific for the sexual-stage Pfs48/45 antigen. , 2001, Experimental parasitology.
[55] I. Felger,et al. Limited polymorphism in Plasmodium falciparum sexual-stage antigens. , 2001, The American journal of tropical medicine and hygiene.
[56] R. Sinden. Sexual development of malarial parasites. , 1983, Advances in parasitology.